Key statistics
On Thursday, Can-Fite Biopharma Ltd (CANF:TLV) closed at 2.70, 8.00% above its 52-week low of 2.50, set on Sep 30, 2024.
52-week range
Open | 2.70 |
---|---|
High | 2.80 |
Low | 2.70 |
Bid | 2.70 |
Offer | 2.80 |
Previous close | 2.70 |
Average volume | 6.39m |
---|---|
Shares outstanding | 2.04bn |
Free float | 2.04bn |
P/E (TTM) | -- |
Market cap | 55.10m ILS |
EPS (TTM) | -0.0176 ILS |
Data delayed at least 20 minutes, as of Nov 14 2024 15:24 GMT.
More ▼
- Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
- Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
- Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
- FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
- Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
- Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
- Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
- Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
- Can-Fite Provides Namodenoson Patent Update
- Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
More ▼